HC Wainwright Lowers Earnings Estimates for Sanara MedTech

Sanara MedTech Inc. (NASDAQ:SMTI) – Analysts at HC Wainwright cut their Q1 2026 earnings per share estimates for shares of Sanara MedTech in a research note issued on Thursday, April 2nd. HC Wainwright analyst Y. Chen now anticipates that the company will earn ($0.04) per share for the quarter, down from their previous estimate of $0.13. HC Wainwright currently has a “Buy” rating and a $36.00 target price on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.10) per share. HC Wainwright also issued estimates for Sanara MedTech’s Q2 2026 earnings at $0.02 EPS, Q3 2026 earnings at $0.06 EPS and FY2026 earnings at $0.16 EPS.

Sanara MedTech (NASDAQ:SMTI) last posted its quarterly earnings data on Tuesday, March 24th. The company reported $0.04 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.07). Sanara MedTech had a negative net margin of 36.42% and a negative return on equity of 20.73%. The company had revenue of $27.55 million for the quarter, compared to the consensus estimate of $27.90 million.

Other research analysts have also issued research reports about the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sanara MedTech in a research report on Thursday, January 22nd. Wall Street Zen lowered Sanara MedTech from a “buy” rating to a “hold” rating in a research report on Sunday. Finally, Zacks Research lowered Sanara MedTech from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 20th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Sanara MedTech has a consensus rating of “Hold” and a consensus target price of $36.00.

Sanara MedTech Stock Down 2.2%

SMTI stock traded down $0.38 on Tuesday, reaching $16.81. 10,994 shares of the company traded hands, compared to its average volume of 64,393. Sanara MedTech has a one year low of $16.05 and a one year high of $35.95. The company has a debt-to-equity ratio of 7.75, a current ratio of 1.80 and a quick ratio of 1.59. The company has a market cap of $154.15 million, a P/E ratio of -3.97 and a beta of 1.10. The firm has a fifty day simple moving average of $19.41 and a 200-day simple moving average of $23.56.

Institutional Trading of Sanara MedTech

A number of institutional investors and hedge funds have recently modified their holdings of SMTI. BNP Paribas Financial Markets increased its holdings in shares of Sanara MedTech by 351.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,504 shares of the company’s stock worth $48,000 after purchasing an additional 1,171 shares in the last quarter. Wells Fargo & Company MN increased its holdings in shares of Sanara MedTech by 78.1% in the 4th quarter. Wells Fargo & Company MN now owns 3,322 shares of the company’s stock worth $78,000 after purchasing an additional 1,457 shares in the last quarter. Lazard Asset Management LLC increased its holdings in shares of Sanara MedTech by 63,100.0% in the 2nd quarter. Lazard Asset Management LLC now owns 3,160 shares of the company’s stock worth $89,000 after purchasing an additional 3,155 shares in the last quarter. Deutsche Bank AG increased its holdings in shares of Sanara MedTech by 171.1% in the 4th quarter. Deutsche Bank AG now owns 3,985 shares of the company’s stock worth $93,000 after purchasing an additional 2,515 shares in the last quarter. Finally, Bank of America Corp DE increased its holdings in shares of Sanara MedTech by 44.1% in the 3rd quarter. Bank of America Corp DE now owns 3,181 shares of the company’s stock worth $101,000 after purchasing an additional 973 shares in the last quarter. Institutional investors own 8.10% of the company’s stock.

About Sanara MedTech

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.